Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019
Daniela K van Santen(Burnet Institute), Margaret Hellard(The Alfred Hospital), Maria-Bernarda Requena(Inserm), Anders Boyd, Marina B. Klein(Royal Victoria Regional Health Centre), Rachel Sacks‐Davis(Burnet Institute), Jim Young(McGill University), Juan Berenguer(Instituto de Salud Carlos III), Colette Smit(Stichting HIV Monitoring), Inmaculada Jarrín(Instituto de Salud Carlos III), Joseph Doyle(The Alfred Hospital), Olivier Leleux(Université de Bordeaux), Maria Prins(University of Amsterdam), Dominique Salmon(Assistance Publique – Hôpitaux de Paris), Ashleigh Stewart(Burnet Institute), Gail Matthews(UNSW Sydney), Fabrice Bonnet(Centre Hospitalier Universitaire de Bordeaux), Jason Asselin(Burnet Institute), Karine Lacombe(Inserm), Mark Stoové(Monash University), Dominique L. Braun(University of Zurich), Andri Rauch(University of Bern), Jeffrey V. Lazarus(The Graduate Center, CUNY), Linda Wittkop(Université de Bordeaux), Marc van der Valk(Academic Medical Center), Tim Spelman(Peter Doherty Institute)
Cited by 38
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
|Nature Immunology|2022|987